Cabozantinib as the causative agent of high-grade fever in a patient with a background of metastatic clear cell renal cell carcinoma: a case report

Abstract Background Fever, as an adverse event, is well documented in a wide array of drugs including multiple tyrosine kinase inhibitors however, it is not a previously well described consequence of the novel multi-targeted tyrosine kinase inhibitor, cabozantinib. Case presentation In this paper we...

Full description

Bibliographic Details
Main Authors: H. M. N. Chen, M. Morris, P. M. Manders
Format: Article
Language:English
Published: BMC 2020-11-01
Series:Journal of Medical Case Reports
Subjects:
Online Access:http://link.springer.com/article/10.1186/s13256-020-02560-0
id doaj-4602779d99b64a668cda4f84bc4140c8
record_format Article
spelling doaj-4602779d99b64a668cda4f84bc4140c82020-11-25T04:11:20ZengBMCJournal of Medical Case Reports1752-19472020-11-011411410.1186/s13256-020-02560-0Cabozantinib as the causative agent of high-grade fever in a patient with a background of metastatic clear cell renal cell carcinoma: a case reportH. M. N. Chen0M. Morris1P. M. Manders2Sunshine Coast University HospitalSunshine Coast University HospitalSunshine Coast University HospitalAbstract Background Fever, as an adverse event, is well documented in a wide array of drugs including multiple tyrosine kinase inhibitors however, it is not a previously well described consequence of the novel multi-targeted tyrosine kinase inhibitor, cabozantinib. Case presentation In this paper we document the first detailed review of high-grade fevers in a 54 year old male (Caucasian) with a background of metastatic clear cell renal cell carcinoma recently commenced on cabozantinib. After detailed investigation, we exclude infection and other common causes of fever as the causative agent and further, definitively resolve the recurrent fever by ceasing cabozantinib and starting a short course of oral corticosteroids. Conclusions We have demonstrated that cabozantinib should always be considered in the aetiology of high-grade fever in relevant patients. Further, we demonstrate that temporary cessation of cabozantinib and a course of short-term steroids can induce resolution of fever and allow for recommencement of cabozantinib safely thereafter.http://link.springer.com/article/10.1186/s13256-020-02560-0CabozantinibRenalFeverCase report
collection DOAJ
language English
format Article
sources DOAJ
author H. M. N. Chen
M. Morris
P. M. Manders
spellingShingle H. M. N. Chen
M. Morris
P. M. Manders
Cabozantinib as the causative agent of high-grade fever in a patient with a background of metastatic clear cell renal cell carcinoma: a case report
Journal of Medical Case Reports
Cabozantinib
Renal
Fever
Case report
author_facet H. M. N. Chen
M. Morris
P. M. Manders
author_sort H. M. N. Chen
title Cabozantinib as the causative agent of high-grade fever in a patient with a background of metastatic clear cell renal cell carcinoma: a case report
title_short Cabozantinib as the causative agent of high-grade fever in a patient with a background of metastatic clear cell renal cell carcinoma: a case report
title_full Cabozantinib as the causative agent of high-grade fever in a patient with a background of metastatic clear cell renal cell carcinoma: a case report
title_fullStr Cabozantinib as the causative agent of high-grade fever in a patient with a background of metastatic clear cell renal cell carcinoma: a case report
title_full_unstemmed Cabozantinib as the causative agent of high-grade fever in a patient with a background of metastatic clear cell renal cell carcinoma: a case report
title_sort cabozantinib as the causative agent of high-grade fever in a patient with a background of metastatic clear cell renal cell carcinoma: a case report
publisher BMC
series Journal of Medical Case Reports
issn 1752-1947
publishDate 2020-11-01
description Abstract Background Fever, as an adverse event, is well documented in a wide array of drugs including multiple tyrosine kinase inhibitors however, it is not a previously well described consequence of the novel multi-targeted tyrosine kinase inhibitor, cabozantinib. Case presentation In this paper we document the first detailed review of high-grade fevers in a 54 year old male (Caucasian) with a background of metastatic clear cell renal cell carcinoma recently commenced on cabozantinib. After detailed investigation, we exclude infection and other common causes of fever as the causative agent and further, definitively resolve the recurrent fever by ceasing cabozantinib and starting a short course of oral corticosteroids. Conclusions We have demonstrated that cabozantinib should always be considered in the aetiology of high-grade fever in relevant patients. Further, we demonstrate that temporary cessation of cabozantinib and a course of short-term steroids can induce resolution of fever and allow for recommencement of cabozantinib safely thereafter.
topic Cabozantinib
Renal
Fever
Case report
url http://link.springer.com/article/10.1186/s13256-020-02560-0
work_keys_str_mv AT hmnchen cabozantinibasthecausativeagentofhighgradefeverinapatientwithabackgroundofmetastaticclearcellrenalcellcarcinomaacasereport
AT mmorris cabozantinibasthecausativeagentofhighgradefeverinapatientwithabackgroundofmetastaticclearcellrenalcellcarcinomaacasereport
AT pmmanders cabozantinibasthecausativeagentofhighgradefeverinapatientwithabackgroundofmetastaticclearcellrenalcellcarcinomaacasereport
_version_ 1724418086859177984